

USSN: 10/625,204

**AMENDMENTS TO THE CLAIMS:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A method for increasing an immune response in an animal, comprising administering a compound which binds to a protein with the amino acid sequence of SEQ ID NO: 2 on the surface of a dendritic cell, wherein said compound is bound to an antigen.
2. (original) The method of claim 1 wherein said animal is a mammal.
3. (original) The method of claim 2 wherein said mammal is a human.
4. (canceled).
5. (previously presented) The method of claim 1 wherein said antigen is bound to said compound by a) covalent binding, b) ligand-ligand interaction, c) complexing, d) ligation, or e) expression of a fusion protein comprising said antigen and said compound.
6. (previously presented) The method of claim 1 wherein said antigen is a cancer antigen.
7. (original) The method of claim 6 wherein said method generates an immune response against tumor cells containing or expressing said cancer antigen.
8. (previously presented) The method of claim 1 wherein said compound is selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, an antibiotic, a sugar, a protein, and an antibody.
9. (withdrawn) The method of claim 8 wherein said mannose carbohydrate is mannan or D-mannose.
10. (withdrawn) The method of claim 8 wherein said fucose carbohydrate is L-fucose.
11. (canceled).
12. (withdrawn) The method of claim 8 wherein said antibiotic is pradimicin A.

USSN: 10/625,204

13. (withdrawn) The method of claim 8 wherein said sugar is selected from the group consisting of N-acetyl-D-glucosamine and galactose.

14. (withdrawn) The method of claim 8 wherein said protein is selected from the group consisting of gp120, analogs of gp120 and fragments of gp120.

Claims 15 – 17 (canceled).

18. (original) The method of claim 8 wherein said antibody is a monoclonal antibody.

Claims 19 – 21 (canceled).

22. (previously presented) The method of claim 8 wherein said antibody is selected from the group consisting of i) an antibody produced by hybridoma ECACC accession number 99040818 and ii) an antibody produced by hybridoma ECACC accession number 99040819.

23. (previously presented) A method for generating an immune response against tumor cells in an animal, the method comprising administering a compound which binds to a protein with the amino acid sequence of SEQ ID NO: 2 on the surface of a dendritic cell, the compound having at least a portion of a cancer antigen attached thereto.